Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.

Whitehurst CB, Sanders MK, Law M, Wang FZ, Xiong J, Dittmer DP, Pagano JS.

J Virol. 2013 May;87(9):5311-5. doi: 10.1128/JVI.03505-12. Epub 2013 Feb 28.

2.
3.

Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS.

J Virol. 2009 Dec;83(23):12108-17. doi: 10.1128/JVI.01575-09. Epub 2009 Sep 16.

4.

Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase.

Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T.

Virology. 2009 Jun 20;389(1-2):75-81. doi: 10.1016/j.virol.2009.04.007. Epub 2009 May 8.

5.

BGLF4 kinase modulates the structure and transport preference of the nuclear pore complex to facilitate nuclear import of Epstein-Barr virus lytic proteins.

Chang CW, Lee CP, Su MT, Tsai CH, Chen MR.

J Virol. 2015 Feb;89(3):1703-18. doi: 10.1128/JVI.02880-14. Epub 2014 Nov 19.

7.

Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4.

Zhu J, Liao G, Shan L, Zhang J, Chen MR, Hayward GS, Hayward SD, Desai P, Zhu H.

J Virol. 2009 May;83(10):5219-31. doi: 10.1128/JVI.02378-08. Epub 2009 Feb 25.

8.

SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.

Li R, Wang L, Liao G, Guzzo CM, Matunis MJ, Zhu H, Hayward SD.

J Virol. 2012 May;86(10):5412-21. doi: 10.1128/JVI.00314-12. Epub 2012 Mar 7.

9.

DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.

Wang'ondu R, Teal S, Park R, Heston L, Delecluse H, Miller G.

PLoS One. 2015 May 7;10(5):e0126088. doi: 10.1371/journal.pone.0126088. eCollection 2015.

10.

The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC.

J Virol. 2010 May;84(9):4534-42. doi: 10.1128/JVI.02487-09. Epub 2010 Feb 24.

11.

Phosphoproteomic Profiling Reveals Epstein-Barr Virus Protein Kinase Integration of DNA Damage Response and Mitotic Signaling.

Li R, Liao G, Nirujogi RS, Pinto SM, Shaw PG, Huang TC, Wan J, Qian J, Gowda H, Wu X, Lv DW, Zhang K, Manda SS, Pandey A, Hayward SD.

PLoS Pathog. 2015 Dec 29;11(12):e1005346. doi: 10.1371/journal.ppat.1005346. eCollection 2015 Dec.

13.

Effect of Pinus massoniana Lamb. bark extract on lytic cycle of Epstein-Barr virus.

Xu S, Zhang S, Wang X, Gao Y, Qin X, Wu K.

Indian J Exp Biol. 2012 Oct;50(10):708-13.

PMID:
23214264
14.

Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.

Verma D, Thompson J, Swaminathan S.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3609-14. doi: 10.1073/pnas.1523686113. Epub 2016 Mar 14.

15.

The Epstein-Barr virus protein kinase BGLF4 and the exonuclease BGLF5 have opposite effects on the regulation of viral protein production.

Feederle R, Mehl-Lautscham AM, Bannert H, Delecluse HJ.

J Virol. 2009 Nov;83(21):10877-91. doi: 10.1128/JVI.00525-09. Epub 2009 Aug 26.

16.

Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.

Goswami R, Gershburg S, Satorius A, Gershburg E.

Antiviral Res. 2012 Dec;96(3):296-304. doi: 10.1016/j.antiviral.2012.09.021. Epub 2012 Oct 8.

17.

Epstein-Barr virus protein kinase BGLF4 targets the nucleus through interaction with nucleoporins.

Chang CW, Lee CP, Huang YH, Yang PW, Wang JT, Chen MR.

J Virol. 2012 Aug;86(15):8072-85. doi: 10.1128/JVI.01058-12. Epub 2012 May 23.

18.

Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: structure-activity relationships.

Lin JC, Cherng JM, Hung MS, Baltina LA, Baltina L, Kondratenko R.

Antiviral Res. 2008 Jul;79(1):6-11. doi: 10.1016/j.antiviral.2008.01.160. Epub 2008 Mar 31.

PMID:
18423902
19.

(-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.

Liu S, Li H, Chen L, Yang L, Li L, Tao Y, Li W, Li Z, Liu H, Tang M, Bode AM, Dong Z, Cao Y.

Carcinogenesis. 2013 Mar;34(3):627-37. doi: 10.1093/carcin/bgs364. Epub 2012 Nov 24.

PMID:
23180656
20.

Characterization of Epstein-Barr virus BGLF4 kinase expression control at the transcriptional and translational levels.

Wang JT, Chuang YC, Chen KL, Lu CC, Doong SL, Cheng HH, Chen YL, Liu TY, Chang Y, Han CH, Yeh SW, Chen MR.

J Gen Virol. 2010 Sep;91(Pt 9):2186-96. doi: 10.1099/vir.0.019729-0. Epub 2010 May 5.

PMID:
20444992

Supplemental Content

Support Center